AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia
Completed
- Conditions
- Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure
- Interventions
- Drug: Sodium Polystyrene Sulphonate 15g/60 mL water
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 147
- Registration Number
- NCT04566653
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 57
- Registration Number
- NCT04564027
- Locations
- 🇪🇸
Research Site, Madrid, Spain
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
Phase 1
Completed
- Conditions
- Mantle Cell LymphomaCOVID-19
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT04564040
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
Phase 3
Completed
- Conditions
- Heart FailureAcute Myocardial Infarction
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4017
- Registration Number
- NCT04564742
- Locations
- 🇬🇧
Research Site, Worthing, United Kingdom
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
Active, not recruiting
- Conditions
- Ovarian CancerProstate Cancer
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1013
- Registration Number
- NCT04560452
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT04556760
- Locations
- 🇩🇪
Research Site, Neuss, Germany
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 138
- Registration Number
- NCT04556773
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
Recruiting
- Conditions
- Prostate CancerOvarian CancerBreast CancerPancreatic Cancer
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT04553926
- Locations
- 🇰🇷
Research Site, Yongin, Korea, Republic of
A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol
Phase 1
Completed
- Conditions
- Chronic Kidney Disease
- Interventions
- Drug: Verinurad/Allopurinol FDC Capsule
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT04550234
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
Phase 3
Active, not recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: PlaceboRadiation: Radiation
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 640
- Registration Number
- NCT04550260
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
© Copyright 2025. All Rights Reserved by MedPath